Maxcyte (MXCT) Long-Term Deferred Tax (2024 - 2025)
Maxcyte (MXCT) posted quarterly Long-Term Deferred Tax of $39.5 million for Q4 2025, up 2487.03% year-over-year from $1.5 million in Q4 2024, and up 2487.03% quarter-over-quarter from $1.5 million in Q4 2024.
Maxcyte (MXCT) Long-Term Deferred Tax (2024 - 2025) Analysis & Trends
Maxcyte (MXCT) has reported Long-Term Deferred Tax for 2 consecutive years, with $39.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Long-Term Deferred Tax rose 2487.03% year-over-year to $39.5 million; the TTM figure through Dec 2025 stood at $39.5 million (up 2487.03% YoY), while the FY2025 annual figure was $39.5 million, up 2487.03% from the prior year.
- Long-Term Deferred Tax climbed to $39.5 million in Q4 2025 per MXCT's latest filing, from $1.5 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $39.5 million in Q4 2025 and bottomed at $1.5 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn |
| 10 | Maxcyte | 147.95 Mn | 147.95 Mn | 5.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 39.50 Mn |
| Dec 31, 2024 | 1.53 Mn |